The Psychedelic News Feed

In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:

• Usona Institute files its psilocybin for major depressive disorder new drug application with FDA
• FDA approves NRx Pharmaceuticals’ preservative-free generic ketamine
• We share our analysis of 610 public comments on FDA’s psychedelics docket
• ICER is set to review Compass Pathways’ psilocybin for treatment-resistant depression
• More takeaways from The Psychedelic Healthcare Forum
• Other stories

Read more:

• Usona Files Psilocybin for Depression NDA as Race With Compass Tightens
• Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket
• FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending
• Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum
• Take part in Johns Hopkins’ psychedelic research survey

The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.

This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at http://ubc.com.

Send us your questions and comments at pod@psychedelicalpha.com

Read more and join our newsletter at https://psychedelicalpha.com

Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.

Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/

In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:

• Early Notes from The Psychedelic Healthcare Forum
• FDA Floats an Ibogaine Trial Design, Asks Field for Input
• Compass Talks Pricing, Label and a Slow Launch
• New Mexico Nears Medical Psilocybin Launch
• Six More Potential Psychedelic Brand Names

Read more:

• Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
• The Psychedelic Practitioner Issue 7: Preparedness (Systems)

The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.

This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at http://ubc.com.

Send us your questions and comments at pod@psychedelicalpha.com

Read more and join our newsletter at https://psychedelicalpha.com

Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.

Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/

In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through another busy two-week period in the field, including:

• Oregon Health Authority’s decision to shelve its proposed doubling of fees levied on state-regulated psilocybin entities (ft. Taylor West, Exec. Director, Healing Advocacy)
• California carves out $4.7M for psychedelic research
• The DEA again moves to schedule 5 tryptamines
• The PATH Caucus publishes its RFI white paper
• Stanford and UCSF researchers call for “more aggressive” blinding in psychedelic trials (ft. Joshua Woolley, UCSF)

Read more:

• Psychedelic Bulletin 232: Oregon Backpedals Psilocybin Fee Hike; DEA Again Moves to Schedule 5 Tryptamines

The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.

This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at http://ubc.com.

Send us your questions and comments at pod@psychedelicalpha.com

Read more and join our newsletter at https://psychedelicalpha.com

Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.

Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/

In the first episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through a very busy two-week period in the field, including:

• Three meetings, or what I’m calling ‘Psychedelics Week’, in D.C.: FDA’s public hearing, an ibogaine-related meeting hosted by ARPA-H, and a congressional briefing
• A commentary published by top FDA staff outlining a model for psychedelic drug development
• New Zealand’s approval of two psychiatrists to prescribe MDMA
• And many other headlines, including: Definium Therapeutics’ Phase 3 LSD for generalised anxiety disorder readout, more data from Compass Pathways’ psilocybin for treatment-resistant depression program, Xylo’s neuroplastogen enters the clinic, Eli Lilly’s acquisition of AtaiBeckley closes, RFK Jr. hosts Bryan Hubbard on his podcast to talk ibogaine, and Usona Institute files a trademark on ‘Arumaya’ a potential brand name for its psilocybin candidate.

Read more:

• No Questions Asked: FDA’s Psychedelics Public Hearing
• ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
• Psychedelic Bulletin 231
• Field Notes #5: 'Psychedelics Week' in Washington D.C.
• Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD
• Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.

This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at http://ubc.com.

Send us your questions and comments at pod@psychedelicalpha.com

Read more and join our newsletter at https://psychedelicalpha.com

Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.

Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/